EZH2 and synovial sarcoma: While cell line-based xenograft studies yielded further evidence for the anti-synovial sarcoma activity of EZH2 inhibitor, inconsistencies in drug efficacy were seen among the mouse models implanted with primary tumor tissues from different synovial sarcoma patients [28].